CrystalGenomics aiming to take on celecoxib as novel COX-2 inhibitor moves forward
This article was originally published in Scrip
Executive Summary
CrystalGenomics has begun a US Phase IIb trial for its most advanced development project CG100649, a "next-generation" COX-2 inhibitor it believes has benefits over the current big sellers in the class such as celecoxib (Pfizer's Celebrex).